Validation of a multi-gene qPCR-based pharmacogenomics panel across major ethnic groups in Singapore and Indonesia
Aim: The clinical utility of pharmacogenomics (PGx) has been gaining traction alongside growing evidence that adverse drug reactions (ADRs) have significant genetic associations. Nala PGx Core® is a multi-gene qPCR-based panel of 20 allele variants, comprising 18 SNPs and two CYP2D6 copy number markers across four pharmacogenes - CYP2C9, CYP2C19, CYP2D6 and SLCO1B1. Methods: In this study, we validated the performance of Nala PGx Core® against benchmark methods, on the Singaporean and Indonesian populations. Results & conclusion: Nala PGx Core® demonstrated robust and accurate genotyping when compared with other established benchmarks. Furthermore, the panel successfully characterized alleles of clinical relevance, such as CYP2D6*10 and CYP2D6*36, across major ethnic groups present of Singapore and Indonesia, suggesting its potential for adoption in clinical workflows regionally.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 22(2021), 16 vom: 03. Nov., Seite 1041-1056 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kothary, Anar Sanjaykumar [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.02.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/pgs-2021-0071 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332338282 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332338282 | ||
| 003 | DE-627 | ||
| 005 | 20231225215355.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2021-0071 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1107.xml |
| 035 | |a (DE-627)NLM332338282 | ||
| 035 | |a (NLM)34693729 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kothary, Anar Sanjaykumar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Validation of a multi-gene qPCR-based pharmacogenomics panel across major ethnic groups in Singapore and Indonesia |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.02.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: The clinical utility of pharmacogenomics (PGx) has been gaining traction alongside growing evidence that adverse drug reactions (ADRs) have significant genetic associations. Nala PGx Core® is a multi-gene qPCR-based panel of 20 allele variants, comprising 18 SNPs and two CYP2D6 copy number markers across four pharmacogenes - CYP2C9, CYP2C19, CYP2D6 and SLCO1B1. Methods: In this study, we validated the performance of Nala PGx Core® against benchmark methods, on the Singaporean and Indonesian populations. Results & conclusion: Nala PGx Core® demonstrated robust and accurate genotyping when compared with other established benchmarks. Furthermore, the panel successfully characterized alleles of clinical relevance, such as CYP2D6*10 and CYP2D6*36, across major ethnic groups present of Singapore and Indonesia, suggesting its potential for adoption in clinical workflows regionally | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Validation Study | |
| 650 | 4 | |a CYP2C19 | |
| 650 | 4 | |a CYP2C9 | |
| 650 | 4 | |a CYP2D6 | |
| 650 | 4 | |a SLCO1B1 | |
| 650 | 4 | |a Southeast Asia | |
| 650 | 4 | |a adverse drug reactions | |
| 650 | 4 | |a genetic associations | |
| 650 | 4 | |a genomic DNA | |
| 650 | 4 | |a molecular diagnostics | |
| 650 | 7 | |a Cytochrome P-450 CYP2C19 |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 CYP2D6 |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 700 | 1 | |a Mahendra, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Mingchen |e verfasserin |4 aut | |
| 700 | 1 | |a Min Tan, Eunice Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Hong Yi, Jacelyn Phua |e verfasserin |4 aut | |
| 700 | 1 | |a Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Hui Jocelyn, Tan Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Haruman, Jessline Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Zhihao |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Chun Kiat |e verfasserin |4 aut | |
| 700 | 1 | |a Lezhava, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Benedict |e verfasserin |4 aut | |
| 700 | 1 | |a Irwanto, Astrid |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 22(2021), 16 vom: 03. Nov., Seite 1041-1056 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:16 |g day:03 |g month:11 |g pages:1041-1056 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2021-0071 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 16 |b 03 |c 11 |h 1041-1056 | ||